Synapsoft logo
AI Insights from Disclosures
Searching...
Aptabio Therapeutics Inc. 293780
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
Aptabio Therapeutics Inc. is a platform technology-based 'First-in-Class' new drug development company that develops innovative new drugs targeting the global market based on three proprietary platform technologies: the Oxidative stress modulation platform, the CAF Modulation platform, and the Aptamer-drug conjugate (Apta-DC) platform. Research and development is operated under an open innovation concept, with drug candidate discovery research and the control tower role carried out by its own research personnel, while stage-by-stage basic research and clinical research are carried out in collaboration with a Scientific Advisory Board (SAB) group that uses external industry-academia-research institute-hospital organizations.
Representative Director Lee Sujin
Founded July 24, 2009
Corporation Type KOSDAQ
Industry Classification Research and experimental development on medical sciences and pharmacy
Corporate number 13581-0168906
Business number 135-86-03821
Phone Number 031-365-3693
Fax Number 031-211-6697
Website www.aptabio.com
Company Address 13 Heungdeok 1-ro, Giheung-gu, Yongin-si, Gyeonggi-do
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant